| Autor: |
Ahronovich, M D, Erickson, K, Baron, I S, Baker, R, Litman, F R |
| Zdroj: |
Pediatric Research; November 2010, Vol. 68 Issue: 1, Number 1 Supplement 1 p221-221, 1p |
| Abstrakt: |
Background and aims: Controversy exists regarding dexamethasone treatment in preterm infants with respiratory failure. We assessed the relationship between dexamethasone (DEX) exposure and length of treatment with intellectual outcome in extremely low birth weight newborns (< 1000 g; ELBW).Design/methods: We studied 57 ELBW and 90 term-born children at age 3 (2004-2006 births). There were three groups of ELBW participants: NODEX (untreated; n=38); short-course DEX (1- 16 days; n=14); and long-course DEX (17-42 days; n=5). DEX treatment was limited to use in infants with severe respiratory failure who were =21 days of age and =27 weeks corrected gestation. General intelligence (Differential Ability Scales-II General Conceptual Ability [GCA]) scores age adjusted for prematurity < 85 were coded as impaired. Chisquare test compared impairment rates.Results: Impairment rates (IQ< 85) were: 6.7% for term-born; 13.2% for NODEX; 14.2% for short-course; and 60.0% for long-course (Chisquare= 14.46, p=.002). Post-hoc comparisons indicate NODEX and short-course groups did not differ significantly while long-course resulted in significantly higher impairment rates compared to both NODEX (p=.01) and short-course groups (p=.002).FigureConclusions: We found short-course dexamethasone treatment did not increase the risk of intellectual impairment in ELBW children at age 3. Concerns regarding developmental outcome may be warranted but should not preclude consideration of short-term dexamethasone treatment for severe respiratory failure in ELBW infants. However, treatment extended beyond 16 days significantly increased the risk of intellectual impairment. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
